Weglim-M1 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The extended-release formulation of Weglim-M1 Forte ensures a gradual release of active ingredients, promoting sustained plasma concentrations and improved patient compliance through once-daily dosing. This combination therapy is particularly beneficial for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve target glycemic levels. Clinical use of Weglim-M1 Forte should be accompanied by lifestyle modifications including diet and exercise. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia or lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely lactic acidosis. Regular monitoring of blood glucose, renal function, and patient adherence is essential to optimize therapeutic outcomes and minimize risks. Weglim-M1 Forte Tablet PR offers an effective and convenient option for comprehensive glycemic management in type 2 diabetes.